Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KW-2450

Known as: IGF-1R/IR Inhibitor KW-2450 
An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndazolesPiperazines
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2016
2016
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Antitumor Activity of KW-2450 against Triple- NegativeBreastCancerbyInhibitingAuroraAand
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… Expand
Is this relevant?
2013
2013
Abstract 920: KW-2450, a novel IGF-1R/IR inhibitor, enhances the antitumor effect of lapatinib, letrozole or 4-hydroxy-tamoxifen in breast cancer cells.
[Background] Both the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptors (IR) have been found to be promising… Expand
Is this relevant?
2013
2013
Abstract P2-09-04: Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC)
Recent studies found that TNBC had a highly activated profile in the insulin-like growth factor 1 receptor (IGF-1R)/insulin… Expand
Is this relevant?
2013
2013
Abstract 2431: IGF1R/IR axis is a novel treatment target in ER-negative breast cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background/Hypothesis: Insulin growth factor-1… Expand
Is this relevant?
2011
2011
Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors.
3078 Background: KW-2450, a potent small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist… Expand
Is this relevant?
2011
2011
Abstract 3605: KW-2450, a novel orally-active dual IGF1R/IR inhibitor: Antitumor effects in vitro and in vivo
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL KW-2450 is an orally active, multi-kinase inhibitor… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE